In the latest quarter, 6 analysts provided ratings for Boston Scientific (NYSE:BSX), showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	3	3	0	0	0
Last 30D	0	1	0	0	0
1M Ago	0	1	0	0	0
2M Ago	2	1	0	0	0
3M Ago	1	0	0	0	0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $122.83, with a high estimate of $132.00 and a low estimate of $100.00. Observing a downward trend, the current average is 5.52% lower than the prior average price target of $130.00.

Exploring Analyst Ratings: An In-Depth Overview

The standing of Boston Scientific among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Matt Miksic	Barclays	Lowers	Overweight	$124.00	$136.00
Suraj Kalia	Oppenheimer	Lowers	Outperform	$100.00	$125.00
Richard Newitter	Truist Securities	Lowers	Buy	$120.00	$130.00
William Plovanic	Canaccord Genuity	Lowers	Buy	$131.00	$132.00
Shagun Singh	RBC Capital	Raises	Outperform	$130.00	$125.00
Marie Thibault	BTIG	Maintains	Buy	$132.00	$132.00

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Boston Scientific. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Boston Scientific's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Boston Scientific analyst ratings.

About Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Understanding the Numbers: Boston Scientific's Finances

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Boston Scientific displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 20.34%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Boston Scientific's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.91%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Boston Scientific's ROE excels beyond industry benchmarks, reaching 3.3%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.79%, the company showcases effective utilization of assets.

Debt Management: With a below-average debt-to-equity ratio of 0.51, Boston Scientific adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Significance of Analyst Ratings Explained

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.